Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00725153 · ClinicalTrials.gov registry record · NA
Evaluation of Deposits on Contact Lenses Worn Daily Wear
A NA study, sponsored by Alcon Research.
- Completed
- Registry status
- NA
- Development phase
- 55
- Enrollment target
NCT00725153: Completed NA study, sponsored by Alcon Research.
NCT00725153 is a NA study that has completed, run by Alcon Research. The registered enrollment target is 55 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00725153, a NA study, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- NA
- Development phase
- 55 participants
- Enrollment target
Study Summary
The purpose of this study was to measure front surface deposits on contact lenses when worn for ten hours.
Primary Outcome
Film and discrete deposits were assessed with a slit-lamp after 10 hours of lens wear. Film deposits were recorded on a 5-point scale, where 0=no deposition, clean surface; 1=slight, deposition occupying 1-5% of lens front surface; 2=mild, deposition occupying 6-15% of lens front surface; 3=moderate, deposition occupying 16-25% of lens front surface; 4=severe, deposition occupying \>25% of lens front surface. Discrete deposits were recorded on a 5-point scale, where 0=no deposition, clean surfac
Interventions
- DEVICE Balafilcon A contact lenses (PureVision)
- DEVICE Etafilcon A contact lenses (Acuvue2)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2008-03 |
| Est. Completion | 2008-09 |
| Phase | NA |
What the finished NCT00725153 record still lists
NCT00725153 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which Balafilcon A contact lenses (PureVision) is the first listed.
NCT00725153 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00725153 about?
NCT00725153 is a clinical study titled "Evaluation of Deposits on Contact Lenses Worn Daily Wear". The purpose of this study was to measure front surface deposits on contact lenses when worn for ten hours.
What is the current status of trial NCT00725153?
This trial is currently completed. It is a NA study. The enrollment target is 55 participants. The study started on 2008-03. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00725153?
The interventions under investigation include: Balafilcon A contact lenses (PureVision) (DEVICE), Etafilcon A contact lenses (Acuvue2) (DEVICE).
Who is sponsoring clinical trial NCT00725153?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00725153's enrollment target sits among peer trials
55 1264th of 2000 higher than 733 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia